ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 240 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,030 | -70.1% | 85 | -61.4% | 0.00% | -100.0% |
| Q2 2023 | $10,149 | +31.8% | 220 | +14.6% | 0.00% | 0.0% |
| Q1 2023 | $7,699 | -62.2% | 192 | -56.4% | 0.00% | -66.7% |
| Q4 2022 | $20,385 | +307.7% | 440 | +286.0% | 0.00% | +200.0% |
| Q3 2022 | $5,000 | +150.0% | 114 | +307.1% | 0.00% | – |
| Q1 2022 | $2,000 | 0.0% | 28 | +16.7% | 0.00% | – |
| Q4 2021 | $2,000 | +100.0% | 24 | +242.9% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 7 | -58.8% | 0.00% | – |
| Q4 2019 | $1,000 | -75.0% | 17 | -80.5% | 0.00% | -100.0% |
| Q3 2019 | $4,000 | 0.0% | 87 | +38.1% | 0.00% | 0.0% |
| Q2 2019 | $4,000 | 0.0% | 63 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $4,000 | +100.0% | 63 | 0.0% | 0.00% | +100.0% |
| Q4 2018 | $2,000 | – | 63 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
| Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
| Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
| AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
| EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
| FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
| HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
| Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |